Bringing GI Therapies to Market: Phathom Pharmaceuticals’ Steve Basta скачать в хорошем качестве

Bringing GI Therapies to Market: Phathom Pharmaceuticals’ Steve Basta

Welcome to The Healthcare Technology Report, a leading information source on healthcare technology companies and solutions. In this episode, we speak with Steve Basta, President and CEO of Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal (GI) diseases. The company has licensed exclusive rights in the United States, Europe, and Canada to a potassium-competitive acid blocker (PCAB) and is building its commercial business around therapies for acid-related GI conditions. Steve was appointed President and CEO and joined the Board of Directors in April 2025. He brings more than 25 years of leadership experience across biopharmaceutical, medical device, and digital health companies, including CEO roles at SaNOtize, Mahana Therapeutics, Menlo Therapeutics (now VYNE Therapeutics), AlterG, BioForm Medical, and Merz Aesthetics. I am your host, RJ Lumba. We hope you enjoy the show. If you like the episode, click to follow.